Search Results for "Ofirmev"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Ofirmev. Results 1 to 7 of 7 total matches.
See also: acetaminophen
Intravenous Acetaminophen (Ofirmev)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011 (Issue 1361)
Intravenous Acetaminophen (Ofirmev) ...
The FDA has approved an intravenous (IV) formulation
of acetaminophen (Ofirmev – Cadence) for use in
patients ≥2 years old for management of pain either as
monotherapy (mild to moderate pain) or with an opioid
(moderate to severe pain) and for reduction of fever.
Intravenous Diclofenac (Dyloject)
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
with longer use. Acetaminophen is
available in an IV formulation (Ofirmev) that is infused
over 15 minutes ...
The FDA has approved Dyloject (Hospira), an IV
formulation of the NSAID diclofenac sodium, for use
in adults. It can be administered alone for treatment
of mild to moderate pain or in combination with opioid
analgesics for moderate to severe pain. Dyloject is the
first injectable formulation of diclofenac to become
available in the US.
FDA Warns Against Use of Codeine and Tramadol in Children and Breastfeeding Women
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
in oral and
IV (Ofirmev) formulations.12
Oral oxycodone and hydrocodone are alternatives
to codeine ...
The FDA has issued new warnings about the use of the
opioid analgesics codeine and tramadol in children,
particularly those <12 years old, and in breastfeeding
women due to concerns about the risk of respiratory
depression and death. The FDA previously issued
warnings about these drugs in 2013 and 2015.
IV Meloxicam (Anjeso) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
of ketorolac,
ibuprofen (Caldolor), and acetaminophen (Ofirmev)
are also available for treatment of pain ...
The FDA has approved Anjeso (Baudax Bio), an IV
formulation of the nonsteroidal anti-inflammatory
drug (NSAID) meloxicam, for once-daily treatment
of moderate to severe pain in adults. Oral meloxicam
(Mobic, and others), which is only indicated
for treatment of chronic pain associated with
osteoarthritis or rheumatoid arthritis, has been
available for 20 years. IV formulations of ketorolac,
ibuprofen (Caldolor), and acetaminophen (Ofirmev)
are also available for treatment of pain.
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
Analgesic Dosage1 Class Adverse Effects Comments Cost2
Acetaminophen – generic
Feverall (Taro)
Ofirmev ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Intravenous Acetaminophen/Ibuprofen (Combogesic IV)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
possible.
1. Intravenous acetaminophen (Ofirmev). Med Lett Drugs Ther 2011;
53:26.
2. Intravenous ...
The FDA has approved Combogesic IV (Hikma), an IV
solution containing acetaminophen and ibuprofen, to
treat mild to moderate pain (alone) or moderate to
severe pain (in combination with an opioid) in adults
when IV analgesia is considered clinically necessary.
Single-drug IV solutions containing ibuprofen
(Caldolor) and acetaminophen have been available in
the US for years.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):68-9 doi:10.58347/tml.2024.1701c | Show Introduction Hide Introduction
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
tabs4 1300 mg q8h NSAIDs 1.505
(max 4000 mg/day)
Ofirmev (Mallinckrodt) 10 mg/mL IV soln ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.